Nona Biosciences
Nona supplies antibody discovery and CAR screening for Umoja’s in vivo CAR-T collaboration. The November 2025 agreement assigns subsequent product development and commercialization to Umoja. Nona is labeled an enabling partner, not a separately confirmed clinical CAR-T developer.
Corporate information
- Company entity
- Nona Biosciences
- Headquarters / principal office
- Cambridge, Massachusetts, United States ↗
- Founded
- 2022 ↗
- Ownership / capital status
- Not verifiedNot verified
- Official corporate reference
- https://nonabio.com/nona-biosciences-announces-expansion-of-collaboration-with-umoja-biopharma-to-advance-in-vivo-car-t-cell-therapies/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Nona supplies antibody discovery and CAR screening for Umoja’s in vivo CAR-T collaboration. The November 2025 agreement assigns subsequent product development and commercialization to Umoja. Nona is labeled an enabling partner, not a separately confirmed clinical CAR-T developer.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Nona Biosciences Announces Expansion of Collaboration with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies - Nona Biosciences — official page checked
- Matching company-operated LinkedIn page